The National Stem Cell Foundation (NSCF) has partnered with Summit for Stem Cell to support the development of a patient-specific stem cell therapy for the treatment of Parkinson’s disease at The Scripps Research Institute (TSRI) in San Diego, California. The research project is directed by Dr. Andrés Bratt-Leal in the lab of Dr. Jeanne Loring, Director of the Center for Regenerative Medicine at TSRI. The aim of the research is to use a patient’s own skin cells to create normal dopamine-producing neurons that can be returned to the patient without rejection. Dopamine, a chemical that sends messages to areas of the brain that control movement and coordination, is decreased in Parkinson’s when dopamine-producing neurons malfunction or die. This patient-specific therapy has the potential to halt or reverse the damage of Parkinson’s disease and other neurological disorders, including ALS.
“Scientists Receive Funding to Advance Stem-Cell Based Parkinson’s Therapy”
Drug Discovery and Development, July 27, 2016
Jeanne Loring will be leading a two-year project funded by the California Institute for Regenerative Medicine (CIRM) to support safety and quality tests for a potential stem cell therapy for Parkinson’s disease.